一个带有N-异环环的Pt(II) 复合体诱导了卵巢癌中的铁细胞死亡
Xiaomin Shen1, Yue Peng1, Haixia Zhou2
1School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, PR China.
Journal of inorganic biochemistry
|February 9, 2024
概括
一种新的复合物,PtQ,通过诱导活性氧物种 (ROS) 和铁亡,显示出对抗卵巢癌的希望. 这种新型药物可能会克服西斯的抗药性机制.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 西斯是一种关键的化疗药物,但耐药性限制了它的有效性.
- 了解克服西斯普拉丁耐药性的新机制对于卵巢癌治疗至关重要.
研究的目的:
- 为了合成和表征一种新的 (II) 复合物,PtQ,基于一种氨酸衍生物.
- 研究PtQ在卵巢癌中的抗癌机制,重点关注其绕过西斯普拉丁耐药性的潜力.
主要方法:
- 合成和表征Pt(II) 复合物PtQ. 的合成和表征.
- 用PtQ治疗卵巢癌细胞 (SKOV3) PtQ.
- 对反应性氧物种 (ROS) 生产,铁亡标记物 (SLC7A11,GPX4),DNA损伤 (单链断裂) 和DNA修复蛋白 (PARP1) 表达的测试.
主要成果:
- PtQ诱导过度的ROS产生,触发卵巢癌细胞中的ferroptotic细胞死亡.
- PtQ降低了SLC7A11和GPX4的调节,它们是脂质过氧化的主要调节者.
- PtQ诱导DNA单链断裂,并抑制了PARP1的表达.
- PtQ展示了一种绕过已知的西斯普拉丁抗药途径的机制.
结论:
- 在卵巢癌中,PtQ表现出一种新的抗癌机制,与西斯不同.
- 通过ROS的过度生产和脂质过氧化调节者的下调,PtQ诱导铁.
- 由于PtQ能够绕过西斯普拉丁抗药途径,这为卵巢癌提供了潜在的新疗法策略.
相关概念视频
Electron Transport Chain: Complex I and II
13.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.3K
Necrosis
4.5K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.5K
Overview of Cell Death
7.3K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.3K
The Electron Transport Chain
16.7K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
16.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


